The transcription factor C/EBPα shows the greatest dominant-repressive effect on small heterodimer partner (SHP) expression in HepG2 and human hepatocytes, leading to the progression and severity of NAFLD (Benet et al., 2015). Here, NR0B2 is linked to metabolic dysfunction-associated steatotic liver disease.